Network-Driven Drug Discovery.

We describe an approach to early stage drug discovery that explicitly engages with the complexities of human biology. The combined computational and experimental approach is formulated on a conceptual framework in which network biology is used to bridge between individual molecular entities and the cellular phenotype that emerges when those entities interact in a network. Multiple aspects of early stage discovery are addressed including the data-driven elucidation of biological processes implicated in disease, target identification and validation, phenotypic discovery of active molecules and their mechanism of action, and extraction of genetic target support from human population genetics data. Validation is described via summary of a number of discovery projects and details from a project aimed at COVID-19 disease.

[1]  Andrew M. Gross,et al.  Network-based stratification of tumor mutations , 2013, Nature Methods.

[2]  Jessen T. Havill,et al.  Networks , 1995, Discovering Computer Science.

[3]  A. Hopkins.  Network pharmacology , 2007, Nature Biotechnology.

[4]  Jack W Scannell,et al.  When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis , 2016, PloS one.

[5]  J. Hopfield,et al.  From molecular to modular cell biology , 1999, Nature.

[6]  John G. Moffat,et al.  Phenotypic screening in cancer drug discovery — past, present and future , 2014, Nature Reviews Drug Discovery.

[7]  Noah J. Cowan,et al.  Nodal Dynamics, Not Degree Distributions, Determine the Structural Controllability of Complex Networks , 2011, PloS one.

[8]  Mulin Jun Li,et al.  Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .

[9]  E. Schadt.  Molecular networks as sensors and drivers of common human diseases , 2009, Nature.

[10]  Michael Bryce,et al.  Test 5.14.4. Deposit 18 June 15:43, embargoed 18/07/2019 : Article -> Review article , 2019 .

[11]  Emily A King,et al.  Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval , 2019, PLoS genetics.

[12]  R. Sharan,et al.  Protein networks in disease. , 2008, Genome research.

[13]  Guilhem Semerjian,et al.  Network dismantling , 2016, Proceedings of the National Academy of Sciences.

[14]  Yuan Qi,et al.  Modularity and Dynamics of Cellular Networks , 2006, PLoS Comput. Biol..

[15]  H. Kitano.  A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.

[16]  Wei Jiang,et al.  The analysis of the drug–targets based on the topological properties in the human protein–protein interaction network , 2009, Journal of drug targeting.

[17]  G. Edelman,et al.  Degeneracy and complexity in biological systems , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Pangalos,et al.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.

[19]  Albert-László Barabási,et al.  Error and attack tolerance of complex networks , 2000, Nature.

[20]  Yang I Li,et al.  An Expanded View of Complex Traits: From Polygenic to Omnigenic , 2017, Cell.

[21]  M. Prunotto,et al.  Opportunities and challenges in phenotypic drug discovery: an industry perspective , 2017, Nature Reviews Drug Discovery.

[22]  J. Cummings,et al.  Alzheimer's disease drug development pipeline: 2017 , 2017, Alzheimer's & dementia.

[23]  Teresa M. Przytycka,et al.  Chapter 5: Network Biology Approach to Complex Diseases , 2012, PLoS Comput. Biol..

[24]  Stuart L Schreiber,et al.  The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods. , 2016, Cell chemical biology.

[25]  E. Chakravarty,et al.  Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study , 2020, EClinicalMedicine.